The Association Between Cervical Cancer Screening and Cancer Occurrence
NCT ID: NCT01015079
Last Updated: 2009-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6000000 participants
OBSERVATIONAL
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
NCT00728871
The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus
NCT00154479
Screening and Identification of Biomarkers on Cervical Cancers
NCT00854269
Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions
NCT00872937
The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients
NCT00155077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Entire Taiwan women
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Part I:
* Include women covered by national screening program and they did not have previous cervical cancer history before the study initiate date.
Part II:
* Include women ever participated cervical cancer screening and exclude women with previous cervical cancer history before screening attending.
Part III:
* Include women without previous cervical cancer history before the follow-up initiation.
Part IV:
* Include women without previous cervical cancer history before the follow-up initiation.
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Department of Health, Executive Yuan, R.O.C. (Taiwan)
OTHER_GOV
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National Taiwan University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chi-An Chen, MD
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taiwan Cervical Cancer Screening Task Force
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Cheng WF, Chen YL, You SL, Chen CJ, Chen YC, Hsieh CY, Chen CA. Risk of gynaecological malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening population. BJOG. 2011 Jan;118(1):34-41. doi: 10.1111/j.1471-0528.2010.02769.x. Epub 2010 Nov 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200910043R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.